Low Testosterone Is Associated With Nonalcoholic Steatohepatitis and Fibrosis Severity in Men
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
With rising prevalence of obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) is now a leading cause of chronic liver disease. One-third of obese or diabetic men have subnormal free and bioavailable testosterone concentrations.1 Several studies have further shown low testosterone to be associated with imaging-confirmed NAFLD in men,2 although it is unknown whether low testosterone confers increased risk of more clinically relevant manifestations of NAFLD, including nonalcoholic steatohepatitis (NASH) and NASH fibrosis. We therefore aimed to evaluate the association of testosterone with histologic features of NAFLD among a representative cohort of men from the multicenter NASH Clinical Research Network (NASH CRN).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Critical Evaluation of Simple Methods for the Estimation of Free Testosterone in Serum
Vermeulen, A., Verdonck, L., & Kaufman, J. M. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.10.6079 · Cited by 3,824
Identification of late-onset hypogonadism in middle-aged and elderly men
Wu, F. C. W., Tajar, A., Beynon, J. M., Pye, S. R., Silman, A. J., Finn, J. D., O'Neill, T. W., Bartfai, G., Casanueva, F. F., Forti, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911101 · Cited by 1,544 · cited 1×
“We also selected a conservative cut-off to define “low testosterone” that is below the threshold where hypogonadal symptoms typically develop(4).”
BackgroundKapoor, D., Goodwin, E., Channer, K. S., & Jones, T. H. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02166 · Cited by 791 · cited 1×
“Testosterone replacement in men also improves insulin resistance, lipids, and visceral adiposity, supporting a more direct role of testosterone on metabolic risk factors for NAFLD/NASH (1, 6, 7).”
Background(2017) · PubMed · doi:10.5604/16652681.1235481 · Cited by 111 · cited 2×
“Several studies have demonstrated lower testosterone levels in men with NAFLD, and/or an independent association low testosterone with imaging-confirmed NAFLD in men (2, 5).”
BackgroundSarkar, M., VanWagner, L. B., Terry, J. G., Carr, J. J., Rinella, M., Schreiner, P. J., Lewis, C. E., Terrault, N., & Cohort, F. T. C. A. R. D. I. Y. A. (. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000138 · Cited by 37
Self-citation
Research works printed but not linked: 4
- Dhindsa, 2018, Hypogonadotropic hypogonadism in men with diabesity, Diabetes Care, 41, 1516, 10.2337/dc17-2510 · DOI · Paper page
- Dhindsa, 2016, Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes, Diabetes Care, 39, 82, 10.2337/dc15-1518 · DOI · Paper page
- Fujihara, 2019, High sex hormone-binding globulin concentration is a risk factor for high fibrosis-4 index in middle-aged Japanese men, Endocr J, 66, 637, 10.1507/endocrj.EJ18-0505 · DOI
- Vermeulen, 1999, A critical evaluation of simple methods for the estimation of free testosterone in serum, J Clin Endocrinol Metab, 84, 3666, 10.1210/jcem.84.10.6079 · DOI · Paper page
Cited by
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Therapeutic pipeline in nonalcoholic steatohepatitis
Vuppalanchi, R., Noureddin, M., Alkhouri, N., & Sanyal, A. J. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00408-y · Cited by 278
Lonardo, A., & Suzuki, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051278 · Cited by 129
Self-citationPhan, H., Richard, A., Lazo, M., Nelson, W. G., Denmeade, S. R., Groopman, J., Kanarek, N., Platz, E. A., & Rohrmann, S. (2021) · Liver International · doi:10.1111/liv.14652 · Cited by 45
Pharmacological treatment of MASLD: contemporary treatment and future perspectives
Drygalski, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136518 · Cited by 39
“Its anti-inflammatory effects further help suppress hepatic production of pro-inflammatory cytokines and reduce oxidative stress, both of which play a role in the transition from simple steatosis to steatohepatitis and fibrosis [138–140].”
Sex differences in chronic liver disease and benign liver lesions
Cooper, K. M., Delk, M., Devuni, D., & Sarkar, M. (2023) · JHEP Reports · doi:10.1016/j.jhepr.2023.100870 · Cited by 38
Self-citation
Metadata
- Authors
- Sarkar, M., Yates, K., Suzuki, A., Lavine, J., Gill, R., Ziegler, T., Terrault, N., & Dhindsa, S.
- Venue
- Clinical Gastroenterology and Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 19
- Issue
- 2
- Pages
- 400-402.e2
- ISSN
- 1542-3565 (ISSN-L)
- OpenAlex
- W2993057096
- Cited by
- 71
- References
- 5
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (DK111944)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.